Sarah Yentz

Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis

Alexi Vasbinder, YeeAnn Chen, Adrien Procureur et al. · JACC CardioOncology · 2022 · 80 citations · Full text

Life Sciences, Immunology, Pathology +12

Teleoncology for Veterans: High Patient Satisfaction Coupled With Positive Financial and Environmental Impacts

Cindy Jiang, Garth W. Strohbehn, Rachel Dedinsky et al. · JCO Oncology Practice · 2021 · 50 citations

Medicine, Oncology, Radiation Oncology +17

Clinical Correlates of Benefit From Radium‐223 Therapy in Metastatic Castration Resistant Prostate Cancer

Ajjai Alva, Luke T. Nordquist, Stephanie Daignault et al. · The Prostate · 2016 · 48 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer

Alex K. Bryant, K. Nathan Sankar, Garth W. Strohbehn et al. · Lung Cancer · 2021 · 36 citations · Full text

Life Sciences, Immunology, Oncology +17

Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial).

Zachery R. Reichert, Michael Devitt, Joshi J. Alumkal et al. · Journal of Clinical Oncology · 2022 · 23 citations

Medicine, Oncology, Urology +15